Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain
tumour in humans and has a very poor prognosis. The existing treatments have had limited …

Radiation oncology exploits the biological interaction of radiation within tissue to promote
tumor death while minimizing damage to surrounding normal tissue. The clinical delivery of …

PURPOSE: Development of a radiosensitivity predictive assay is a central goal of radiation
oncology. We reasoned a gene expression model could be developed to predict intrinsic …

Erlotinib (Tarceva) is an orally available HER1 (epidermal growth factor receptor, EGFR)
tyrosine kinase inhibitor advancing through clinical trials for the treatment of a range of …

PURPOSE: The discovery of effective biomarkers is a fundamental goal of molecular
medicine. Developing a systems–biology understanding of radiosensitivity can enhance our …

Diffuse intrinsic pontine glioma (DIPG) is one of the most frequent malignant pediatric brain
tumor and its prognosis is universaly fatal. No significant improvement has been made in …

The tyrosine kinase inhibitor imatinib (Gleevec, Novartis Pharmaceuticals Corporation;
Basel, Switzerland) is a powerful drug for treatment of chronic myelogenous leukemia (CML) …

Homologous recombination serves multiple roles in DNA repair that are essential for
maintaining genomic stability. We here describe RI-1, a small molecule that inhibits the …

Purpose We performed a phase II study to evaluate the combination of imatinib mesylate, an
adenosine triphosphate mimetic, tyrosine kinase inhibitor, plus hydroxyurea, a …

Purpose: Histone deacetylase (HDAC) inhibitors, which modulate chromatin structure and
gene expression, represent a class of anticancer agents that hold particular potential as …